Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2016, Article ID 4692139, 8 pages
http://dx.doi.org/10.1155/2016/4692139
Clinical Study

Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?

1University of Alabama at Birmingham School of Medicine, Birmingham, AL 35233, USA
2Biostatistics Division, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233, USA
3Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA
4Liver Transplant and Hepatobiliary Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA

Received 25 September 2015; Revised 21 December 2015; Accepted 29 December 2015

Academic Editor: Kalpesh Jani

Copyright © 2016 Nathan Haywood et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Forner, J. M. Llovet, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 379, no. 9822, pp. 1245–1255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Lencioni, “Loco-regional treatment of hepatocellular carcinoma,” Hepatology, vol. 52, no. 2, pp. 762–773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Shah, J. K. Smith, Y. Li, S. C. Ng, J. E. Carroll, and J. F. Tseng, “Underutilization of therapy for hepatocellular carcinoma in the medicare population,” Cancer, vol. 117, no. 5, pp. 1019–1026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Thuluvath, M. K. Guidinger, J. J. Fung, L. B. Johnson, S. C. Rayhill, and S. J. Pelletier, “Liver transplantation in the United States, 1999–2008: special feature,” American Journal of Transplantation, vol. 10, no. 4, part 2, pp. 1003–1019, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Bruix and M. Sherman, “Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar
  6. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. J. Kim, H. J. Kim, J. H. Park et al., “Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma,” Liver International, vol. 34, no. 2, pp. 305–312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Lencioni and J. M. Llovet, “Modified recist (mRECIST) assessment for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 30, no. 1, pp. 52–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Lencioni, “New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma,” Clinical Cancer Research, vol. 19, no. 6, pp. 1312–1314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Arora and A. Kumar, “Treatment response evaluation and follow-up in hepatocellular carcinoma,” Journal of Clinical and Experimental Hepatology, vol. 4, supplement 3, pp. S126–S129, 2014. View at Publisher · View at Google Scholar
  11. B. C. Odisio, F. Galastri, R. Avritscher et al., “Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization,” CardioVascular and Interventional Radiology, vol. 37, no. 4, pp. 1018–1026, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Pauwels, M. Azahaf, G. Lassailly et al., “Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) chemoembolisation before liver transplantation for hepatocellular carcinoma: an imaging/histologic correlation study,” CardioVascular and Interventional Radiology, vol. 38, no. 3, pp. 685–692, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Riaz, L. Kulik, R. J. Lewandowski et al., “Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using Yttrium-90 microspheres,” Hepatology, vol. 49, no. 4, pp. 1185–1193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Shim, S. Han, Y. M. Shin et al., “Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria,” Journal of Vascular and Interventional Radiology, vol. 24, no. 3, pp. 316–325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Bargellini, E. Bozzi, D. Campani et al., “Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants,” European Journal of Radiology, vol. 82, no. 5, pp. e212–e218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Bargellini, C. Vignali, R. Cioni et al., “Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria—selection parameter for liver transplantation,” Radiology, vol. 255, no. 1, pp. 289–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Memon, L. Kulik, R. J. Lewandowski et al., “Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times,” Gastroenterology, vol. 141, no. 2, pp. 526.e2–535.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H. J. Prajapati, J. R. Spivey, S. I. Hanish et al., “mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable Hepatocellular Carcinoma (HCC) treated by Doxorubicin Drug-Eluting Beads Transarterial Chemoembolization (DEB TACE),” Annals of Oncology, vol. 24, no. 4, pp. 965–973, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Gillmore, S. Stuart, A. Kirkwood et al., “EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization,” Journal of Hepatology, vol. 55, no. 6, pp. 1309–1316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. B. K. Kim, S. U. Kim, K. A. Kim et al., “Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma,” Journal of Hepatology, vol. 62, no. 6, pp. 1304–1310, 2015. View at Publisher · View at Google Scholar
  21. K. Han, J. H. Kim, H. M. Yoon et al., “Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival,” Korean Journal of Radiology, vol. 15, no. 4, pp. 464–471, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. H. Shim, H. C. Lee, S.-O. Kim et al., “Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models,” Radiology, vol. 262, no. 2, pp. 708–718, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. White, D. T. Redden, M. K. Bryant et al., “Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma,” HPB, vol. 16, no. 12, pp. 1095–1101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Wald, M. W. Russo, J. K. Heimbach, H. K. Hussain, E. A. Pomfret, and J. Bruix, “New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma,” Radiology, vol. 266, no. 2, pp. 376–382, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Bruix, M. Sherman, J. M. Llovet et al., “Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference,” Journal of Hepatology, vol. 35, no. 3, pp. 421–430, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. Lai, A. W. Avolio, I. Graziadei et al., “Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation,” Liver Transplantation, vol. 19, no. 10, pp. 1108–1118, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. L. De Carlis, S. D. Sandro, A. Giacomoni et al., “Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation?” Journal of Clinical Gastroenterology, vol. 46, no. 1, pp. 78–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Hucke, W. Sieghart, M. Pinter et al., “The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE,” Journal of Hepatology, vol. 60, no. 1, pp. 118–126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. D. J. Kim, P. J. Clark, J. Heimbach et al., “Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size,” American Journal of Transplantation, vol. 14, no. 6, pp. 1383–1390, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Llovet and J. Bruix, “Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival,” Hepatology, vol. 37, no. 2, pp. 429–442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. R. C. Gaba, “Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey,” American Journal of Roentgenology, vol. 198, no. 3, pp. 692–699, 2012. View at Publisher · View at Google Scholar · View at Scopus